Hager Biosciences, LLC

Biotechnology ResearchUnited States2-10 Employees

Hager Biosciences, LLC is a preclinical-stage drug discovery organization practicing innovative discovery medicinal chemistry. Hager's main mission is to become a preferred partner to pharmaceutical and biotech firms by providing therapeutic leads through out-licensing for unmet medical needs. Central to the business model is Hager's capability to design and synthesize proprietary small fragment molecules for modular adaptation into new or existing drug candidate optimization or novelization projects. Hager's discovery FragPhore ® platform provides a competitive and efficient advantage for rapid novel lead generation, optimization and drug rescue via profile/properties improvement, as well as modular fragments swap for intellectual property enhancement.

Hager’s highly cost-effective and efficient discovery research process including using outsourced network infrastructures has a solid track records of innovative preclinical pharmaceutical candidate discovery in CNS therapeutic spaces attested by several IP estates generated. Recent examples of awarded patents as well as filed patent applications from which two clinical candidates are on the verge of entering human clinical trials for Alzheimer diseases include:
11,505,555
10,329,301
11,414,425
10,815,242
11,142,529
11,312,721
16/445,854
63/399,509
WO2020247447
WO2020247445
US2022/0259224
63/403,019
63/400,894

Sign up for free to view info

Email Format Employee directory